Panitumumab clinical trials
Panitumumab is named as an intervention in 20 current clinical trials in our Italy, USA, France, Australia, Spain, Japan, Germany, Canada, South Korea, UK, Netherlands, Belgium, Taiwan, China, Denmark, Austria, Mexico, Switzerland, Czechia, Brazil, Israel, Sweden, Poland, Portugal, Turkey and Egypt registers. 17 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Amgen (4). The most-studied condition is Metastatic Colorectal Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Panitumumab is approved
All regulators →Of the three regulators tracked here, the first to approve Panitumumab was the US, on 27 Sep 2006. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Panitumumab
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Panitumumab works
All drug targets →- Epidermal growth factor receptor erbB1 inhibitor InhibitorTarget: EGFR epidermal growth factor receptor✓ In ChEMBL and the Guide to Pharmacology
- Colon carcinomaPhase 3
- Gastric cancerPhase 3
- Gastric neoplasmPhase 3
- Head and neck squamous cell carcinomaPhase 3
- Hypopharynx squamous cell carcinomaPhase 3
- Laryngeal squamous cell carcinomaPhase 3
- Malignant colon neoplasmPhase 3
- Metastatic colorectal cancerPhase 3
- Oral cavity squamous cell carcinomaPhase 3
- Oropharynx squamous cell carcinomaPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1201827, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6883, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Panitumumab
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 3 technology appraisals of Panitumumab. 3 are current, and 1 of these recommend it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer NICE TA439 | Recommended | 29 Mar 2017 Updated 25 Sep 2017 | Current |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy NICE TA242 | Not recommended | 25 Jan 2012 | Current |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) NICE TA240 | Terminated (no company submission) | 14 Dec 2011 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Panitumumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 1 product on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: VectibixEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Panitumumab
- ATC code
- L01XC08
- ChEMBL
- CHEMBL1201827
- DrugBank
- DB01269
- CAS number
- 339177-26-3
- FDA UNII
- 6A901E312A
- Wikidata
- Q417775
- Wikipedia
- Panitumumab
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Panitumumab
20 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Panitumumab in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Panitumumab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
2026-526473-42-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Authorised | Verastem Inc | Italy, Spain, France + 2 more |
Panitumumab across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
1 single-substance product containing Panitumumab on the HPRA medicines list.
- Vectibix 20 mg/mL concentrate for solution for infusionAmgen Europe B.V., · EU/1/07/423/001-003
Supply shortages
No entry for Panitumumab in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Panitumumab
31 conditionsAll 31 conditions
| Condition (as registered) | Trials |
|---|---|
| Metastatic Colorectal Cancer | 4 |
| Colorectal Cancer | 3 |
| Advanced Solid Tumors | 2 |
| Advanced Malignant Solid Neoplasm | 2 |
| KRAS Altered Advanced or Metastatic Solid Tumors | 1 |
| Kirsten Rat Sarcoma (KRAS) pG12C Mutation | 1 |
| Solid Tumor | 1 |
| Non-Small-Cell Lung Cancer | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Metastatic Solid Tumors | 1 |
| Non-small Cell Lung Cancer | 1 |
| Histiocytic Neoplasm | 1 |
| Histiocytosis | 1 |
| BRAF Gene Mutation | 1 |
| Colon Cancer Stage II | 1 |
| Colon Cancer Stage III | 1 |
| Metastatic Gastroesophageal Adenocarcinoma | 1 |
| DPD Deficiency | 1 |
| Colorectal Neoplasms | 1 |
| Resectable Colorectal Carcinoma | 1 |
| Colorectal Cancer Stage IV | 1 |
| Colorectal Cancer Metastatic | 1 |
| Objective Responsive Rate (ORR) | 1 |
| Cancer | 1 |
| Tumors | 1 |
| Neoplasm | 1 |
| Neoplasia | 1 |
| Metastatic Malignant Solid Neoplasm | 1 |
| Anatomic Stage III Breast Cancer AJCC v8 | 1 |
| Anatomic Stage IV Breast Cancer AJCC v8 | 1 |
| Locally Advanced Malignant Solid Neoplasm | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Panitumumab trials
How many clinical trials are testing Panitumumab?
20 current trials in our Italy, USA, France, Australia, Spain, Japan, Germany, Canada, South Korea, UK, Netherlands, Belgium, Taiwan, China, Denmark, Austria, Mexico, Switzerland, Czechia, Brazil, Israel, Sweden, Poland, Portugal, Turkey and Egypt registers name Panitumumab (also registered as ERAS-0015 in combination) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Panitumumab trials recruiting patients?
Yes. 17 of the 20 trials are recruiting: 10 with sites in Italy, 7 with sites in USA, 8 with sites in France, 6 with sites in Australia, 6 with sites in Spain, 6 with sites in Japan, 4 with sites in Germany, 4 with sites in Canada, 4 with sites in South Korea, 3 with sites in UK, 3 with sites in Netherlands, 3 with sites in Belgium, 3 with sites in Taiwan, 3 with sites in China, 3 with sites in Denmark, 2 with sites in Austria, 2 with sites in Mexico, 2 with sites in Switzerland, 2 with sites in Czechia, 2 with sites in Brazil, 2 with sites in Israel, 1 with sites in Sweden, 1 with sites in Poland, 1 with sites in Portugal, 1 with sites in Turkey and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Panitumumab clinical trials?
Amgen (4), National Cancer Institute, Naples (2), National Cancer Institute (NCI) (2) and AbbVie (1), among 15 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Panitumumab licensed in Ireland?
Yes. The HPRA medicines list includes 1 single-substance product containing Panitumumab, for example Vectibix 20 mg/mL concentrate for solution for infusion (Amgen Europe B.V.,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Panitumumab shortage?
Not in the lists we track: Panitumumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Panitumumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Panitumumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Panitumumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.